Search - tctmd.com

Displaying 1 - 20 of 36

Sort: Relevancy | Date

News Conference News TCT 2021

FAVOR III China Adds Strength to Value of QFR-Guided PCI

L.A. McKeown

November 04, 2021

News Conference News TCT 2021

FAME 3: PCI Fails to Demonstrate Noninferiority to Surgery in Three-Vessel CAD

Michael O'Riordan

November 04, 2021

News Conference News TCT 2020

Prophylactic PCI of Vulnerable Plaques? PROSPECT II/ABSORB

Michael O'Riordan

October 14, 2020

News Conference News TCT 2019

EXCEL at 5 Years: PCI for Left Main CAD Still Noninferior to CABG

Marcus A. Banks

September 28, 2019

Even With PSP, Bioresorbable Scaffold Falls Short in ABSORB-COMPARE and ABSORB IV Trials

News Conference News TCT 2018

Even With PSP, Bioresorbable Scaffold Falls Short in COMPARE-ABSORB and ABSORB IV Trials

Michael O'Riordan

September 25, 2018

News Opinion Editor's Corner TCT 2018

TCT 2018, Day Four: Bioresorbable Scaffolds, Renal Denervation, Head-to-Head TAVR, INOCA, and . . . That’s a Wrap!

Shelley Wood

September 25, 2018

News Conference News TCT 2018

PCI vs CABG at 10 Years: MAIN-COMPARE and SYNTAXES Shine Light on Long-term Outcomes

Michael O'Riordan

September 25, 2018

News Conference News TCT 2018

EXCEL Deep Dive: Repeat Revascularization, Medical Therapy, and Anemia All Impact Patient Prognosis

Michael O'Riordan

September 21, 2018

News Conference News TCT 2017

Long-term Absorb BVS Data Continue to Disappoint

Michael O'Riordan

October 31, 2017

News Conference News TCT 2017

No Advantage With Hybrid Revascularization for Multivessel Disease: HREVS

Michael O'Riordan

October 30, 2017

News Conference News TCT 2017

Compared With Provisional Stenting, Double-Kissing Crush Technique Reduces Left Main Disease Events at 1 Year

Yael L. Maxwell

October 30, 2017

News Conference News TCT 2016

EXCEL y NOBLE: Los Resultados Contrarios Plantean un Dilema a la Hora de Elegir entre PCI y CABG en el Manejo de la Enfermedad de Tronco Coronario Izdo.

Michael O'Riordan

October 31, 2016

News Conference News TCT 2016

EXCEL and NOBLE: Opposing Results Pose Quandary for PCI/CABG Choice in Left Main Disease

Michael O'Riordan

October 31, 2016

Presentation TCT 2016

EXCEL: A Prospective, Randomized Trial Comparing Everolimus-Eluting Stents and Bypass Graft Surgery in Selected Patients With Left Main Coronary Artery Disease

Presenter: Martin B. Leon, Keith G. Oldroyd, Gregg W. Stone

October 31, 2016

News Conference News TCT 2016

BIONICS: Ridaforolimus-Eluting Stent Noninferior to Zotarolimus Stent at 1 Year

TCT Daily Staff

October 30, 2016

Presentation TCT 2016

BIONICS: A Prospective, Randomized Trial of a Ridaforolimus-Eluting Coronary Stent vs a Zotarolimus-Eluting Stent in a More-Comers Population of Patients With Coronary Artery Disease

Presenter: Gregg W. Stone, Wayne B. Batchelor, David E. Kandzari

October 30, 2016

Presentation TCT 2016

BIO-RESORT (TWENTE III): A Prospective, Randomized Three-Arm Trial Comparing Two Different Biodegradable Polymer-Based Drug-Eluting Stents and a Durable Polymer-Based Drug-Eluting Stent in an All-Comers Population of Patients With Coronary Artery Disease

Presenter: Gregg W. Stone, Wayne B. Batchelor, Clemens von Birgelen

October 30, 2016

News Conference News TCT 2015

PANDA III: BuMA SES Noninferior to Excel SES for TLF at 1 Year

October 14, 2015

News Conference News TCT 2015

ABSORB III: Novel Bioresorbable Scaffold as Good as Standard-of-Care DES

Yael L. Maxwell

October 12, 2015

News Conference News TCT 2015

Absorb BVS Matches Xience V in Chinese Patients

Todd Neale

October 12, 2015

Advertisement

FAVOR III China Adds Strength to Value of QFR-Guided PCI

FAME 3: PCI Fails to Demonstrate Noninferiority to Surgery in Three-Vessel CAD

Prophylactic PCI of Vulnerable Plaques? PROSPECT II/ABSORB

EXCEL at 5 Years: PCI for Left Main CAD Still Noninferior to CABG

Even With PSP, Bioresorbable Scaffold Falls Short in COMPARE-ABSORB and ABSORB IV Trials

TCT 2018, Day Four: Bioresorbable Scaffolds, Renal Denervation, Head-to-Head TAVR, INOCA, and . . . That’s a Wrap!

PCI vs CABG at 10 Years: MAIN-COMPARE and SYNTAXES Shine Light on Long-term Outcomes

EXCEL Deep Dive: Repeat Revascularization, Medical Therapy, and Anemia All Impact Patient Prognosis

Long-term Absorb BVS Data Continue to Disappoint

No Advantage With Hybrid Revascularization for Multivessel Disease: HREVS

Compared With Provisional Stenting, Double-Kissing Crush Technique Reduces Left Main Disease Events at 1 Year

EXCEL y NOBLE: Los Resultados Contrarios Plantean un Dilema a la Hora de Elegir entre PCI y CABG en el Manejo de la Enfermedad de Tronco Coronario Izdo.

EXCEL and NOBLE: Opposing Results Pose Quandary for PCI/CABG Choice in Left Main Disease

EXCEL: A Prospective, Randomized Trial Comparing Everolimus-Eluting Stents and Bypass Graft Surgery in Selected Patients With Left Main Coronary Artery Disease

BIONICS: Ridaforolimus-Eluting Stent Noninferior to Zotarolimus Stent at 1 Year

BIONICS: A Prospective, Randomized Trial of a Ridaforolimus-Eluting Coronary Stent vs a Zotarolimus-Eluting Stent in a More-Comers Population of Patients With Coronary Artery Disease

BIO-RESORT (TWENTE III): A Prospective, Randomized Three-Arm Trial Comparing Two Different Biodegradable Polymer-Based Drug-Eluting Stents and a Durable Polymer-Based Drug-Eluting Stent in an All-Comers Population of Patients With Coronary Artery Disease

PANDA III: BuMA SES Noninferior to Excel SES for TLF at 1 Year

ABSORB III: Novel Bioresorbable Scaffold as Good as Standard-of-Care DES

Absorb BVS Matches Xience V in Chinese Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content